Chelse Spinner1, Lili Ding2,3, David I Bernstein2,3, Darron R Brown4, Eduardo L Franco5, Courtney Covert3, Jessica A Kahn6,3. 1. University of Cincinnati. 2. College of Medicine, Cincinnati, Ohio. 3. Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 4. Indiana University, Indianapolis, Indiana; and. 5. McGill University, Montreal, Canada. 6. College of Medicine, Cincinnati, Ohio; jessica.kahn@cchmc.org.
Abstract
BACKGROUND: Clinical trials of the 4-valent human papillomavirus (HPV) vaccine demonstrate high efficacy, but surveillance studies are essential to examine the long-term impact of vaccine introduction on HPV prevalence in community settings. The aims of this study were to determine during the 11 years after vaccine introduction the prevalence of (1) vaccine-type HPV in adolescent and young adult women who were vaccinated (to assess vaccine effectiveness) and (2) vaccine-type HPV in women who were unvaccinated (to assess herd protection). METHODS: Young women 13 to 26 years of age were recruited from hospital-based and community health clinics for 4 surveillance studies from 2006 to 2017. We determined the proportion of vaccinated and unvaccinated women who were positive for vaccine-type HPV across the studies, and the odds of positivity for vaccine-type HPV using logistic regression; all analyses were propensity score-adjusted to control for between-wave differences in participant characteristics. RESULTS: Vaccination rates increased from 0% to 84.3% (97% of study participants received the 4-valent vaccine). Among women who were vaccinated, 4-valent vaccine-type HPV detection decreased from 35% to 6.7% (80.9% decline; odds ratio 0.13, 95% confidence interval 0.08 to 0.22). Among women who were unvaccinated, 4-valent vaccine-type HPV detection decreased from 32.4% to 19.4% (40% decline; odds ratio 0.50, 95% confidence interval 0.26 to 0.97). Estimated vaccine effectiveness was 90.6% in wave 3 and 80.1% in wave 4. CONCLUSIONS: In this study in which trends in HPV in a US community >10 years after 4-valent HPV vaccine introduction and after 9-valent vaccine introduction were examined, we found evidence of vaccine effectiveness and herd protection. Further research is needed to examine trends in 9-valent vaccine-type HPV after higher rates of vaccination are achieved.
BACKGROUND: Clinical trials of the 4-valent human papillomavirus (HPV) vaccine demonstrate high efficacy, but surveillance studies are essential to examine the long-term impact of vaccine introduction on HPV prevalence in community settings. The aims of this study were to determine during the 11 years after vaccine introduction the prevalence of (1) vaccine-type HPV in adolescent and young adult women who were vaccinated (to assess vaccine effectiveness) and (2) vaccine-type HPV in women who were unvaccinated (to assess herd protection). METHODS: Young women 13 to 26 years of age were recruited from hospital-based and community health clinics for 4 surveillance studies from 2006 to 2017. We determined the proportion of vaccinated and unvaccinated women who were positive for vaccine-type HPV across the studies, and the odds of positivity for vaccine-type HPV using logistic regression; all analyses were propensity score-adjusted to control for between-wave differences in participant characteristics. RESULTS: Vaccination rates increased from 0% to 84.3% (97% of study participants received the 4-valent vaccine). Among women who were vaccinated, 4-valent vaccine-type HPV detection decreased from 35% to 6.7% (80.9% decline; odds ratio 0.13, 95% confidence interval 0.08 to 0.22). Among women who were unvaccinated, 4-valent vaccine-type HPV detection decreased from 32.4% to 19.4% (40% decline; odds ratio 0.50, 95% confidence interval 0.26 to 0.97). Estimated vaccine effectiveness was 90.6% in wave 3 and 80.1% in wave 4. CONCLUSIONS: In this study in which trends in HPV in a US community >10 years after 4-valent HPV vaccine introduction and after 9-valent vaccine introduction were examined, we found evidence of vaccine effectiveness and herd protection. Further research is needed to examine trends in 9-valent vaccine-type HPV after higher rates of vaccination are achieved.
Authors: Elmar A Joura; Susanne K Kjaer; Cosette M Wheeler; Kristján Sigurdsson; Ole-Erik Iversen; Mauricio Hernandez-Avila; Gonzalo Perez; Darron R Brown; Laura A Koutsky; Eng Hseon Tay; Patricia García; Kevin A Ault; Suzanne M Garland; Sepp Leodolter; Sven-Eric Olsson; Grace W K Tang; Daron G Ferris; Jorma Paavonen; Matti Lehtinen; Marc Steben; Xavier Bosch; Joakim Dillner; Robert J Kurman; Slawomir Majewski; Nubia Muñoz; Evan R Myers; Luisa L Villa; Frank J Taddeo; Christine Roberts; Amha Tadesse; Janine Bryan; Lisa C Lupinacci; Katherine E D Giacoletti; Shuang Lu; Scott Vuocolo; Teresa M Hesley; Richard M Haupt; Eliav Barr Journal: Vaccine Date: 2008-10-16 Impact factor: 3.641
Authors: Lauri E Markowitz; Gui Liu; Susan Hariri; Martin Steinau; Eileen F Dunne; Elizabeth R Unger Journal: Pediatrics Date: 2016-02-22 Impact factor: 7.124
Authors: J W Sellors; A T Lorincz; J B Mahony; I Mielzynska; A Lytwyn; P Roth; M Howard; S Chong; D Daya; W Chapman; M Chernesky Journal: CMAJ Date: 2000-09-05 Impact factor: 8.262
Authors: Elmar A Joura; Sepp Leodolter; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Laura A Koutsky; Suzanne M Garland; Diane M Harper; Grace W K Tang; Daron G Ferris; Marc Steben; Ronald W Jones; Janine Bryan; Frank J Taddeo; Oliver M Bautista; Mark T Esser; Heather L Sings; Micki Nelson; John W Boslego; Carlos Sattler; Eliav Barr; Jorma Paavonen Journal: Lancet Date: 2007-05-19 Impact factor: 79.321
Authors: Courtney Covert; Lili Ding; Darron Brown; Eduardo L Franco; David I Bernstein; Jessica A Kahn Journal: Hum Vaccin Immunother Date: 2019-02-20 Impact factor: 3.452
Authors: Newton Sergio de Carvalho; Roberto José de Carvalho da Silva; Isabel Cristina do Val; Maria Luiza Bazzo; Mariângela Freitas da Silveira Journal: Rev Soc Bras Med Trop Date: 2021-05-17 Impact factor: 1.581
Authors: Heather M Brandt; Beth Sundstrom; Courtney M Monroe; Gabrielle Turner-McGrievy; Chelsea Larsen; Melissa Stansbury; Karen Magradey; Andrea Gibson; Delia Smith West Journal: Vaccines (Basel) Date: 2020-12-10
Authors: Luca Giannella; Giovanni Delli Carpini; Jacopo Di Giuseppe; Giorgio Bogani; Barbara Gardella; Ermelinda Monti; Carlo Antonio Liverani; Alessandro Ghelardi; Salvatore Insinga; Michele Montanari; Francesco Raspagliesi; Arsenio Spinillo; Paolo Vercellini; Elena Roncella; Andrea Ciavattini Journal: Infect Drug Resist Date: 2021-09-16 Impact factor: 4.003